genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2023
Eisai Pharmaceuticals
Drug Discovery
As Biopharma Giants Reshape the Field, Cognition Therapeutics Sees a Place for Its Alzheimer’s Drug
Artificial Intelligence
AI, Cell/Gene Therapy, Precision Medicine Drive Bullish Biotech Investment
Cancer
ImmunoGen Shares Plunge after Phase III Failure of Lead ADC in Ovarian Cancer
Industry News
“Some Hope”: Biogen, Eisai Release Positive Phase II Results for Alzheimer’s Candidate
Cancer
Dr. Reddy’s Buys Ex-Asia Rights to Eisai Cancer Candidate E7777
Cancer
Valeant Buys Targretin’s U.S. Rights from Eisai for $65M+
News
FDA Clears Eisai’s Epilepsy Drug Fycompa
News
Positive Results for Phase III Pediatric Trial with Eisai’s Zonegran Epilepsy Drug
News
Eisai Plans EU Filing for Epilepsy Drug as Monotherapy Following Positive Phase III Data
News
Phase III Study Finds Eisai’s Eritoran Fails to Reduce Mortality in Severe Sepsis
1
2
Page 1 of 2
Scroll Up
Scroll Up
